Infections and infestations
Enzymatica appoints Sana Alajmovic as new CEO
August 12, 2025Research and Development Corporate, Enzymatica, Infections and infestations
The board of directors of Enzymatica has appointed Sana Alajmovic as chief executive officer, succeeding Claus Egstrand. Egstrand will step …
Rollout of world-first gonorrhoea vaccine programme begins under NHS
August 8, 2025Medical Communications 10 Year Health Plan, Genito-Urinary system, Infections and infestations, NHS, gonorrhoea, sexual health, sexually transmitted infections, vaccination
From 4 August, sexual health clinics in England have been able to offer a free vaccine – the 4CMenB vaccine …
Sanome’s AI tool gains certification for early detection of hospital infections
August 7, 2025Business Services, Research and Development AI, Devices, Infections and infestations, Medicines and Healthcare products Regulatory Agency, NHS, Sanome, hospital-acquired infections
Sanome’s MEMORI, an artificial intelligence (AI) medical device that can predict hospital-acquired infections up to 72 hours before they present, …
M42 study highlights positive performance of AI model for tuberculosis screening
August 6, 2025Research and Development AI, Infections and infestations, M42, X-ray, tuberculosis
Healthcare tech company, M42, has published results from one of the largest real-world studies of an artificial intelligence (AI)-powered tuberculosis …
First malaria medicine for infants under 4.5kg receives approval
July 9, 2025Medical Communications, Research and Development Coartem Baby, Infections and infestations, Medicines for Malaria Venture, Novartis, Paediatrics, Swissmedic, malaria
Coartem (artemether-lumefantrine) Baby, or Riamet, has been approved by Swissmedic as the first malaria medicine for newborns and young infants. …
Ochre Bio appoints Elaine Sullivan as senior independent non-executive director
May 30, 2025Research and Development Infections and infestations, Ochre Bio, Oncology, RNA therapeutics, Rare Diseases, appointment, senior independent non-executive director
Ochre Bio has appointed Elaine Sullivan as senior independent non-executive director. She joins the Oxford-based RNA therapeutics company with a …
Cold plasma therapy shown to be 100% effective against pneumonia-causing bacteria
May 19, 2025Research and Development Infections and infestations, MRSA, Viromed Medical, intensive care, lung therapy, ventilator-associated pneumonia (VAP)
A breakthrough in lung therapy has been reported by German biotech company Viromed Medical whose cold plasma treatment has demonstrated …
ENA Respiratory appoints two strategic advisors to support leading project
May 7, 2025Research and Development Ena Respiratory, Infections and infestations, Respirology, strategic adivsors
ENA Respiratory, focused on minimising the impact of viral respiratory infections, has announced the appointment of Kenny Simmen (pictured left) …
FDA grants fast track designation to chlamydia vaccine candidate
March 28, 2025Research and Development FDA, Infections and infestations, Sanofi, chlamydia, vaccination
The US Food and Drug Association (FDA) has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention …
Antibacterial peptides instrumental in efficiency against resistant bacteria
November 18, 2024Research and Development AMR, Chalmers Institute of Technology, Infections and infestations, MRSA, antibacterial peptides
This month, the Chalmers University of Technology in Sweden have published the results of a study demonstrating that resistant bacteria, …
EMA accepts AstraZeneca’s regulatory submission for sipavibart for COVID-19 prevention
July 1, 2024Research and Development COVID-19, EMA, Infections and infestations, coronavirus
AstraZeneca has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application (MAA) for sipavibart under the …
ILiAD Biotechnologies announces collaboration with Emmes Group on phase 3 pertussis vaccine trial
June 25, 2024Research and Development Emmes Group, ILiAD Biotechnologies, Infections and infestations, Vaccine, whooping cough
ILiAD Biotechnologies has announced that it has selected Emmes Group to conduct the upcoming phase 3 trials of its lead …
Gilead shares phase 3 results from HIV prevention trial
June 21, 2024Research and Development Gilead, HIV, Infections and infestations, clinical trial
Gilead Sciences has announced results from an interim analysis of its pivotal, phase 3 PURPOSE 1 trial, which assessed the …
FDA approves Merck’s Capvaxive for prevention of pneumococcal disease
June 18, 2024Medical Communications Capvaxive, FDA, Infections and infestations, Merck, pneumonia
Merck, known as MSD outside of the US and Canada, has announced that the US Food and Drug Administration (FDA) …
Gilead’s Veklury recommended by NICE for COVID-19 treatment
April 9, 2024Medical Communications COVID-19, Gilead Sciences, Infections and infestations, remdesivir
Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has recommended the use of Veklury …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
